Sana Biotechnology (SANA)

• Market cap: $368M
• 1 day: 3.12%
• 5 days: -12.70%
• 1 month: -34.78%
• 3 months: -61.18%
• 6 months: -68.45%
• Year to date: -60.71%
• 1 year: -59.76%
• 5 years: -95.30%
• 10 years: -95.30%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.

Employees: 328

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

52% more call options, than puts

Call options by funds: $9.77M | Put options by funds: $6.42M

26% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 27

5% more funds holding

Funds holding: 147 [Q2] → 154 (+7) [Q3]

1.18% more ownership

Funds ownership: 67.68% [Q2] → 68.86% (+1.18%) [Q3]

13% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 45

22% less capital invested

Capital invested by funds: $819M [Q2] → $638M (-$181M) [Q3]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 3 (-1) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $8 385% upside
• Avg. target: $8 385% upside
• High target: $8 385% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Emily Bodnar 17% 1-year accuracy 26 / 150 met price target

385% upside $8

Buy Reiterated

27 Nov 2024